The patent (US 7,902,152), entitled ‘Use of cobratoxin as an analgesic,’ describes a composition of matter for an analgesia and its method of use.
The method of use is for the treatment of chronic pain, especially to the treatment of heretofore intractable pain as associated with advanced cancer.
Nutra Pharma said that this patent provides protection for the development of Cobratoxin as their top tier analgesic product for the treatment of severe pain.
Nutra Pharma chairman and CEO Rik Deitsch said as they continue their efforts developing treatments for chronic pain using proteins from cobra venom, this patent will provide important ongoing support and protection of the research and development projects.